Latest Ratios: P/E Ratio -19.4x · EV/EBITDA N/A · ROE -95.6%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $524M | $387M | $416M | $167M | $205M | $233M | $252M | $63M | $17M | $21M | $9M |
| Enterprise Value | $537M | $400M | $399M | $158M | $189M | $191M | $256M | $60M | $18M | $17M | $11M |
| P/E Ratio → | -19.42 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.18 | 10.48 | 13.24 | 6.97 | 9.97 | 14.27 | 19.63 | 5.63 | 2.33 | 2.88 | 1.63 |
| P/B Ratio | 17.66 | 13.82 | 16.37 | 7.89 | 5.55 | 4.77 | 105.95 | 13.77 | 11.35 | 3.65 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.81 | 12.72 | 6.59 | 9.21 | 11.71 | 19.94 | 5.34 | 2.38 | 2.29 | 1.83 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.4% | 61.4% | 60.9% | 56.8% | 65.8% | 68.2% | 71.1% | 64.9% | 66.9% | 60.7% | 54.0% |
| Operating Margin | -65.4% | -65.4% | -62.9% | -93.7% | -79.5% | -82.1% | -48.5% | -41.0% | -71.4% | -85.9% | -130.3% |
| Net Profit Margin | -69.1% | -69.1% | -60.3% | -92.2% | -80.0% | -88.4% | -52.9% | -49.4% | -83.8% | -97.1% | -140.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -95.6% | -95.6% | -81.2% | -76.1% | -38.4% | -56.3% | -194.8% | -181.7% | -167.9% | -282.6% | — |
| ROA | -37.3% | -37.3% | -46.2% | -45.0% | -27.1% | -30.3% | -32.7% | -56.0% | -56.7% | -67.3% | -92.2% |
| ROIC | -73.7% | -73.7% | -142.2% | -101.3% | -86.8% | -150.2% | -120.4% | -212.4% | -235.1% | -506.3% | -982.7% |
| ROCE | -41.7% | -41.7% | -61.6% | -53.5% | -29.8% | -30.7% | -36.2% | -65.9% | -68.4% | -91.3% | -219.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.08 | 2.08 | 0.14 | 0.66 | 0.32 | 0.25 | 10.15 | 0.54 | 2.30 | 0.84 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.44 | -0.65 | -0.43 | -0.42 | -0.86 | 1.69 | -0.70 | 0.25 | -0.75 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.12 | -10.12 | — | — | -201.90 | -13.81 | -3.70 | -4.80 | -5.29 | -7.21 | -6.62 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.91 | 5.91 | 3.22 | 4.87 | 7.54 | 13.02 | 7.96 | 2.71 | 3.31 | 2.90 | 2.02 |
| Quick Ratio | 5.13 | 5.13 | 2.56 | 3.80 | 6.17 | 11.98 | 6.95 | 1.86 | 2.27 | 2.37 | 1.43 |
| Cash Ratio | 4.27 | 4.27 | 1.94 | 3.11 | 5.52 | 11.38 | 6.28 | 1.49 | 1.54 | 2.11 | 1.10 |
| Asset Turnover | — | 0.38 | 0.80 | 0.56 | 0.37 | 0.25 | 0.43 | 0.94 | 0.94 | 0.53 | 0.78 |
| Inventory Turnover | 1.71 | 1.71 | 1.79 | 1.31 | 0.75 | 1.05 | 1.15 | 1.22 | 1.16 | 1.25 | 1.49 |
| Days Sales Outstanding | — | 71.70 | 54.80 | 60.09 | 47.33 | 52.33 | 53.52 | 35.47 | 61.25 | 46.96 | 54.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% |
| Shares Outstanding | — | $28M | $27M | $25M | $24M | $21M | $16M | $13M | $11M | $8M | $3M |
High cash burn rate
According to current market data, CLPT trades at a price-to-sales multiple of 14.99, which suggests that investors are pricing in significant future revenue expansion rather than current earnings, as the company continues to operate with a negative P/E ratio of -20.53 based on recent financial filings.
The elevated P/S multiple indicates that the market views ClearPoint as a high-growth biologics-enablement platform rather than a traditional hardware manufacturer. This valuation appears to rely heavily on the successful commercialization of partner gene therapies, as the current lack of positive earnings makes traditional valuation metrics like P/E largely irrelevant for assessing intrinsic value.
As reported in historical financial statements, CLPT's ROIC has remained consistently negative, reaching -14.6% in 2026Q1, which highlights the company's ongoing struggle to generate returns on invested capital while it continues to scale its specialized clinical infrastructure and research and development initiatives.
The persistent negative ROIC suggests that the capital deployed into the business is currently destroying value rather than compounding it. Investors should monitor whether the company can achieve a positive inflection in returns as its biologics pipeline matures and the utilization of its installed base increases over time.
Based on the provided quarterly data, CLPT's cash conversion cycle remains extended at 190 days in 2026Q1, primarily driven by high days inventory outstanding of 166 days, which suggests significant capital is tied up in specialized hardware and cannula inventory awaiting clinical trial deployment.
The high DIO relative to industry peers implies that the company must maintain substantial inventory levels to support its specialized procedural requirements. This inefficiency in working capital management places additional pressure on the company's liquidity, as cash remains trapped in the supply chain for extended periods.
As indicated in recent SEC filings, CLPT's debt-to-equity ratio has climbed to 3.37 in 2026Q1, a sharp increase from 0.14 in 2024Q4, which suggests that the company is increasingly relying on debt financing to fund its operations in the absence of internal cash generation.
The rapid accumulation of debt in a high-interest environment warrants caution, as the company's interest coverage ratio of -6.13 in 2026Q1 demonstrates that it is not currently generating sufficient operating income to service its debt obligations. This leverage profile significantly increases the company's sensitivity to future capital market volatility.
The most commonly misapplied metric for CLPT is the P/E ratio, which obscures the company's true value as a platform-based biologics-enablement play by focusing on current accounting losses that are heavily influenced by aggressive R&D spending and the scaling of a specialized clinical workforce.
Investors should instead focus on the number of active biologics partnerships and procedural utilization rates, as these metrics better reflect the company's long-term revenue durability. Relying on P/E or EV/EBITDA in the current growth phase may lead to an underestimation of the company's strategic value within the CNS gene therapy market.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLPT stock.
ClearPoint Neuro, Inc.'s current P/E ratio is -19.4x. This places it at the 50th percentile of its historical range.
ClearPoint Neuro, Inc.'s return on equity (ROE) is -95.6%. The historical average is -130.5%.
Based on historical data, ClearPoint Neuro, Inc. is trading at a P/E of -19.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
ClearPoint Neuro, Inc. has 61.4% gross margin and -65.4% operating margin.